Ms. Deardorf is an experienced biopharma leader who will lead business development and corporate and commercial strategy as Neutrolis advances NTR-1011 into autoimmune diseases following positive Phase 1a results 

CRNX

Neutrolis Appoints Caren Deardorf as Chief Business & Strategy Officer

Neutrolis hires new CBSO to strengthen pipeline and strategy

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>Ms. Deardorf is an experienced biopharma leader who will lead business development and corporate and commercial strategy as Neutrolis advances NTR-1011 into autoimmune diseases following positive Phase 1a results</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Caren Deardorf has been appointed Chief Business &amp; Strategy Officer at Neutrolis, marking a significant move as the company advances its clinical candidate NTR-1011 into autoimmune diseases. Her extensive biopharma experience in commercialization and strategic leadership may positively influence Neutrolis&#039;s growth trajectory and shareholder value.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Neutrolis appointed Caren Deardorf as CBSO to advance its pipeline.</li><li>Deardorf has over 30 years of biopharma leadership experience.</li><li>NTR-1011 is focused on autoimmune diseases, showing positive Phase 1a results.</li><li>Her leadership is expected to enhance commercial strategy for Neutrolis.</li><li>Deardorf&#039;s experience includes significant roles at prominent biopharma companies.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Neutrolis Inc. (Not mentioned)</strong>: Neutrolis could see enhanced strategic direction with Deardorf&#039;s leadership.</li><li><strong>Crinetics Pharmaceuticals (CRNX)</strong>: Deardorf serves on CRNX&#039;s board, potentially aligning strategic interests.</li></ul>
  </section>

  <section data-block="category">
    <h3>Corporate Developments</h3>
    <p>This news falls under &#039;Corporate Developments&#039; as it reflects significant leadership changes that could influence Neutrolis&#039;s strategic direction. Strong leadership is often critical in the biopharma sector, particularly for companies advancing innovative therapies.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>NTR-1011&#039;s Phase 1a success positions Neutrolis favorably for further development.</li><li>Deardorf&#039;s appointment could attract strategic partnerships, boosting CRNX&#039;s valuation.</li><li>Expect increased market attention on Neutrolis&#039;s progress in autoimmune therapies.</li><li>Further announcements regarding partnerships or funding could drive CRNX&#039;s stock price.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Caren Deardorf appointed CBSO on April 15, 2026.</li><li>Neutrolis focuses on therapies targeting Neutrophil Extracellular Traps (NETs).</li><li>NTR-1011 is positioned for late-stage development in autoimmune diseases.</li><li>Deardorf has a history of successful product launches at major biopharma firms.</li><li>Neutrolis is a clinical-stage biotechnology company.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Consider buying CRNX in anticipation of strategic advancements under Deardorf&#039;s leadership over the next 6-12 months.</p>
  </section>
</section>


<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css"></link><ul><li>Ms. Deardorf is an experienced biopharma leader who will lead business development and corporate and commercial strategy as Neutrolis advances NTR-1011 into autoimmune diseases following positive Phase 1a results<br></br><br></br></li></ul>  <p>CAMBRIDGE, Mass., April  15, 2026  (GLOBE NEWSWIRE) -- Neutrolis Inc. a clinical-stage biotechnology company focused on targeting Neutrophil Extracellular Traps (NETs) for the treatment of autoimmune and inflammatory diseases, today announced the appointment of Caren Deardorf as Chief Business &amp; Strategy Officer (CBSO). Ms. Deardorf will lead corporate and pipeline strategy, business development, and early commercial strategy as the company advances its clinical pipeline.</p>  <p>Ms. Deardorf brings more than 30 years of executive leadership experience, with a strong track record in commercialization, product launches, and scaling organizations.</p>  <p>"Caren is an exceptional leader with a valuable combination of commercial acuity, strategic vision, and executional discipline. She has consistently demonstrated an ability to translate innovation into meaningful, high-impact value," said Anthony Aiudi, PharmD, MBA, Chief Executive Officer of Neutrolis. "I am thrilled to welcome her to our team. Her leadership will be instrumental as we advance our pipeline, expand our strategic partnerships, and position the company for late-stage development and beyond."</p>  <p>"Over the years, I have always been driven to create value for shareholders and ultimately lasting impact for patients," said Caren Deardorf. "That's why I'm especially excited to join Neutrolis at this pivotal moment. I'm eagerly looking forward to what this innovative team can build together as we work to address critical unmet needs in autoimmune diseases."</p>  <p>Ms. Deardorf previously served as Chief Commercial &amp; Strategy Officer at Editas Medicine, Magenta Therapeutics, and Ohana Biosciences, where she led commercial, portfolio, and corporate strategy. Earlier in her career, she held multiple roles of increasing leadership at Biogen, where she was responsible for global product development and commercialization for SPINRAZA&#xAE;, supporting a highly successful global launch. Additionally, Ms. Deardorf has led multiple global product launches (TECFIDERA&#xAE;, TYSABRI&#xAE;, and AVONEX&#xAE;) and brings experience across neurology, immunology, hematology, oncology, and rare diseases.</p>  <p>Ms. Deardorf holds a M.B.A. from the Olin Graduate School of Business at Babson College and a B.S. in Biology from Tufts University. She currently serves on the boards of directors for Crinetics Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/CRNX">CRNX</a>) and Pan-Mass Challenge, a non-profit organization that raises funds for Dana-Farber Cancer Institute.</p>  <p><strong>About Neutrolis Inc.,</strong></p>  <p>Neutrolis is a clinical-stage biotechnology company pioneering a new class of rapid-acting, non-immunosuppressive therapies that directly target Neutrophil Extracellular Traps (NETs), a root cause of tissue damage and chronic inflammation. Unlike conventional approaches that broadly suppress immune responses, Neutrolis's therapies harness the body's own mechanisms to precisely degrade and inactivate NETs, offering broad potential across inflammatory disorders.</p>  <p>For more information, please visit <a href="https://www.globenewswire.com/Tracker?data=QEAhx8eZxixHnZFNpVND0lqkolqw30ZYHcnkeNaS1X_eLzE4jU_a8cgcyRkVU7DKLVZx2P6SEU8P0MmndjxWRjY37xhRD1WiJVP4_9lCxkM=" rel="nofollow" target="_blank">www.neutrolis.com</a>.</p>  <p><strong>Investor Contact / Media Contact:</strong></p>  <p><a href="https://www.globenewswire.com/Tracker?data=wXMxBAJZSdpk71ToKHKXEb1QlXqgNYjewwA5xQUsKMxld8b5a6gJ7EB9J4srzMFJ69-apG-IRgJSIxuEf7CAfEqPoMcrtq8C_8VMpPltElY=" rel="nofollow" target="_blank">ir@neutrolis.com</a> </p> <img alt="" class="__GNW8366DE3E__IMG" src="https://www.globenewswire.com/newsroom/ti?nf=OTY5MDUyNSM3NTM3Mzg4IzIyOTczMTk="></img> <br></br><img alt="" src="https://ml.globenewswire.com/media/MGNhODdlNmItMjRlMS00YWZlLTkzYmQtZTljYWNmZTk5ZDU5LTEzMDg4NjktMjAyNi0wNC0xNS1lbg==/tiny/Neutrolis-Inc-.png" referrerpolicy="no-referrer-when-downgrade"></img><p><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/44cdba09-fdb9-4ee1-b7bf-1dcfe5784800"><img src="https://ml.globenewswire.com/media/44cdba09-fdb9-4ee1-b7bf-1dcfe5784800/small/20180228-opr-or-logos-biz-wd-neutrolis-logo-1-jpg.jpg" border="0" width="150" height="91" alt="Primary Logo"></img></a></p>

Caren Deardorf has been appointed Chief Business & Strategy Officer at Neutrolis, marking a significant move as the company advances its clinical candidate NTR-1011 into autoimmune diseases. Her extensive biopharma experience in commercialization and strategic leadership may positively influence Neutrolis's growth trajectory and shareholder value.

Neutrolis Appoints Caren Deardorf as Chief Business & Strategy Officer

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News